The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Therapies 52

Therapies Disease FDA Trials 52

The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Trials 52

DrugBank

AUGUST 9, 2024

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  This exponential growth is primarily fueled by the escalating global burden of chronic diseases. billion by 2030. trillion by 2028.

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

Drug Target Review

SEPTEMBER 21, 2023

Some report that they believe that if they don’t take the medication, they may develop onchocerciasis-related severe skin diseases and may go blind (river blindness) and would prefer a treatment that does not repeat every year. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). million people no longer require MDA for this debilitating parasitic disease. Setting sights on 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014. Levinson, Ph.D.,

Disease 52

Disease Science Therapies Production 52

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. Preparation of benzoic acid derivatives for treatment of metabolic and liver diseases. Current drugs that treat hyperlipidemia (e.g., twitter +919321316780 call whatsaapp EMAIL.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

MARCH 11, 2021

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

Disease 52

Disease Treatment Laboratories Virus 52

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. CRISPR engineering in organoids for gene repair and disease modelling.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

LifeSciVC

JANUARY 16, 2024

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones. Join the club. Additional trials (e.g.,

Small Molecule 139

Small Molecule Trials Therapies Disease 139

The Pharma Data

APRIL 7, 2021

Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

OCTOBER 29, 2020

Scaling up efforts on the prevention and control of non-communicable diseases (NCDs) can avert over 4.3 before the age of 70) from one of the four main NCDs – cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. million deaths and yield RUB 8.1

Disease 40

Disease Packaging Government Production 40

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

NOVEMBER 5, 2020

Since May, Member States have adopted a number of decisions – the Immunization Agenda 2030, the Decade of Healthy Ageing 2020-2030, as well as initiatives to tackle cervical cancer, tuberculosis, eye care, food safety, intellectual property and influenza preparedness. The WHA will consider a draft resolution ( EB146.R10

International 52

International Compliance Virus Vaccine 52

The Pharma Data

DECEMBER 1, 2020

Many neglected tropical diseases (NTDs) result from diverse types of interactions and often complex cycles of transmission between humans and animals, both vertebrates and invertebrates, and changing social and environmental conditions.

Disease 52

Disease Vaccine Government Science 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.  million deaths associated with it.

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Ophthalmic drugs market size, share & trends analysis report by drug class, by disease (dry eye, glaucoma), by dosage form, by route of administration, by product type (prescription, OTC), by region, and segment forecasts, 2022-2030.

FDA 52

FDA Packaging Compliance Regulations 52

Codon

OCTOBER 27, 2024

The Most Deadly Infectious Disease “Each successive episode of bleeding left him weaker than before,” wrote Mary Doria Russell of Doc Holliday, the gunslinging gambler, in her eponymous book, Doc. .’ ” Doc suffered from tuberculosis, or TB, a bacterial disease caused by Mycobacterium tuberculosis.

Immune Response 77

Immune Response Doctors Disease Laboratories 77

LifeSciVC

APRIL 26, 2024

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. This has long been a feature of biopharma (see 2012 and 2016 posts on oncology and immune-oncology , respectively), but has been exacerbated by the creation of so many new companies.

DNA 110

DNA Science Marketing Clinical Trials 110

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

APRIL 24, 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. Despite the tremendous progress made in combating malaria in the past two decades, one child still dies from the disease every two minutes. Read the reports.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

NOVEMBER 11, 2021

Making Further Health has committed to appreciatively impact the lives and health of 50 million people and engage Boehringer Ingelheim workers by 2030. Centers for Disease Control and Prevention. Atlanta, GA Centers for Disease Control and Prevention,U.S.Dept. National Diabetes Statistics Report, 2020.

International 40

International Disease 40

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% The clinical phase of drug research is especially important because it tests the findings from preclinical studies in real-life conditions within the target disease population with human volunteers. between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

APRIL 22, 2023

Since 1997, WHO and UNICEF have jointly collected information on immunization programmes and vaccine-preventable diseases. In 2020, WHO Member States endorsed the Immunization Agenda 2030 (IA2030), where eJRF data is used to report on the monitoring and evaluation framework that guides immunization strategies at global and regional levels.

Vaccine 40

Vaccine Disease 40

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Therapies 40

Therapies Trials Treatment Disease 40

The Pharma Data

NOVEMBER 16, 2020

Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050. Meeting the following targets by 2030 will place all countries on the path toward elimination: 90% of girls fully vaccinated with the HPV vaccine by 15 years of age.

Vaccine 40

Vaccine Treatment Disease Engineering 40

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

SEPTEMBER 28, 2020

Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. CVD has many causes: from smoking, diabetes, high blood pressure and obesity, to air pollution, genetic risk factors and less common conditions such as Chagas disease. Developing next-generation therapies.

Disease 52

Disease Therapies Treatment Clinical Research 52

The Pharma Data

JULY 11, 2021

Tuberculosis is a disease of poverty, and economic distress with 1.4 Tuberculosis is a disease of poverty, and economic distress with 1.4 High-volume, multi-disease testing systems and innovative diagnostic tests can accelerate eradication efforts and further improve health outcomes for people living with TB.

Disease 52

Disease Laboratories Government Treatment 52

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

MAY 4, 2021

Improving access to quality health care for 30 million people globally living in limited resource settings annually by 2030 through the Lilly 30×30 initiative. Environment (by 2030). Highlights of Lilly ‘s ESG commitments include: Access and Affordability. To learn more about Lilly , please visit us at? www.lilly.com ?and?

Government 52

Government Production Disease 52

The Pharma Data

MARCH 24, 2021

Successfully identifying these people, especially those living with multidrug-resistant TB (MDR-TB), remains one of the most significant obstacles in achieving the United Nations (UN) Sustainable Development Goal of ending TB by 2030. TB is a forgotten respiratory disease that still kills 1.4 Notes to editors. Source link:[link].

Treatment 52

Treatment Disease Government International 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Therapies Clinical Trials Disease 52

PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.

Science 52

Science Laboratories Immune Response Disease 52